Emcure Pharmaceuticals Limited (BOM:544210)
India · Delayed Price · Currency is INR 1,865.90
-14.30 (-0.76%)
At close: Aug 21, 2026
Emcure Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 96,835 | 92,035 | 78,960 | 66,583 | 59,858 | 58,554 | |
Revenue Growth | 18.36% | 16.56% | 18.59% | 11.23% | 2.23% | 16.33% |
Cost of Revenue | 39,282 | 36,571 | 32,225 | 25,357 | 23,185 | 22,864 |
Gross Profit | 57,552 | 55,465 | 46,735 | 41,225 | 36,673 | 35,690 |
Selling, General & Admin | 15,682 | 15,522 | 17,264 | 15,577 | 13,069 | 11,805 |
Other Operating Expenses | 22,943 | 22,057 | 14,782 | 13,351 | 11,597 | 10,562 |
Operating Expenses | 42,876 | 41,729 | 35,887 | 32,052 | 27,459 | 24,835 |
Operating Income | 14,676 | 13,736 | 10,847 | 9,173 | 9,214 | 10,855 |
Interest Expense | -1,485 | -1,437 | -1,302 | -2,032 | -1,849 | -1,470 |
Interest & Investment Income | - | - | 90.44 | 207.59 | 118.34 | 101.97 |
Currency Exchange Gain (Loss) | 1,288 | 1,188 | 437.59 | 203.77 | 190.15 | 367.78 |
Other Non Operating Income (Expenses) | 110.39 | 126.64 | -314.36 | -205.93 | -137.55 | -124.92 |
EBT Excluding Unusual Items | 14,590 | 13,614 | 9,759 | 7,346 | 7,536 | 9,730 |
Gain (Loss) on Sale of Investments | - | - | 58.04 | 25.32 | 1.21 | - |
Gain (Loss) on Sale of Assets | - | - | - | - | -3.33 | -4.08 |
Other Unusual Items | -691.07 | -742.13 | -103.78 | -99.31 | -61.46 | - |
Pretax Income | 13,899 | 12,871 | 9,713 | 7,272 | 7,472 | 9,725 |
Income Tax Expense | 3,709 | 3,459 | 2,639 | 1,997 | 1,854 | 2,700 |
Earnings From Continuing Operations | 10,190 | 9,413 | 7,075 | 5,276 | 5,618 | 7,026 |
Net Income to Company | 10,190 | 9,413 | 7,075 | 5,276 | 5,618 | 7,026 |
Minority Interest in Earnings | -75.81 | -169.08 | -261.35 | -293.92 | -298.26 | -403.56 |
Net Income | 10,114 | 9,244 | 6,813 | 4,982 | 5,320 | 6,622 |
Net Income to Common | 10,114 | 9,244 | 6,813 | 4,982 | 5,320 | 6,622 |
Net Income Growth | 35.90% | 35.67% | 36.76% | -6.36% | -19.66% | 68.86% |
Shares Outstanding (Basic) | 190 | 190 | 187 | 181 | 181 | 181 |
Shares Outstanding (Diluted) | 190 | 190 | 187 | 181 | 181 | 181 |
Shares Change | 0.24% | 1.33% | 3.41% | 0.01% | - | - |
EPS (Basic) | 53.35 | 48.77 | 36.43 | 27.54 | 29.42 | 36.62 |
EPS (Diluted) | 53.35 | 48.77 | 36.43 | 27.54 | 29.42 | 36.62 |
EPS Growth | 35.57% | 33.88% | 32.27% | -6.38% | -19.66% | 68.90% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 5,830 | 6,299 | 8,215 | 3,563 | 3,900 |
Free Cash Flow Per Share | - | 30.76 | 33.68 | 45.42 | 19.70 | 21.57 |
Dividend Per Share | - | 3.600 | 3.000 | - | 2.000 | 3.000 |
Dividend Growth | - | 20.00% | - | - | -33.33% | 200.00% |
Gross Margin | 59.43% | 60.27% | 59.19% | 61.92% | 61.27% | 60.95% |
Operating Margin | 15.16% | 14.92% | 13.74% | 13.78% | 15.39% | 18.54% |
Profit Margin | 10.45% | 10.04% | 8.63% | 7.48% | 8.89% | 11.31% |
Free Cash Flow Margin | - | 6.33% | 7.98% | 12.34% | 5.95% | 6.66% |
EBITDA | 19,046 | 17,886 | 14,121 | 11,805 | 11,446 | 12,911 |
EBITDA Margin | 19.67% | 19.43% | 17.88% | 17.73% | 19.12% | 22.05% |
D&A For EBITDA | 4,370 | 4,150 | 3,274 | 2,632 | 2,232 | 2,057 |
EBIT | 14,676 | 13,736 | 10,847 | 9,173 | 9,214 | 10,855 |
EBIT Margin | 15.16% | 14.92% | 13.74% | 13.78% | 15.39% | 18.54% |
Effective Tax Rate | 26.69% | 26.87% | 27.17% | 27.45% | 24.81% | 27.76% |
Revenue as Reported | 96,945 | 92,162 | 79,633 | 67,021 | 60,317 | 59,189 |
Advertising Expenses | - | - | 2,734 | 2,585 | 1,828 | 1,633 |